These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 21104390)

  • 1. Drug addiction.
    Justinova Z; Panlilio LV; Goldberg SR
    Curr Top Behav Neurosci; 2009; 1():309-46. PubMed ID: 21104390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the endocannabinoid system in drug addiction.
    Maldonado R; Valverde O; Berrendero F
    Trends Neurosci; 2006 Apr; 29(4):225-32. PubMed ID: 16483675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives.
    Fattore L; Spano MS; Deiana S; Melis V; Cossu G; Fadda P; Fratta W
    Brain Res Rev; 2007 Jan; 53(1):1-16. PubMed ID: 16839608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.
    Justinova Z; Munzar P; Panlilio LV; Yasar S; Redhi GH; Tanda G; Goldberg SR
    Neuropsychopharmacology; 2008 Nov; 33(12):2870-7. PubMed ID: 18305459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endogenous cannabinoid system modulates nicotine reward and dependence.
    Merritt LL; Martin BR; Walters C; Lichtman AH; Damaj MI
    J Pharmacol Exp Ther; 2008 Aug; 326(2):483-92. PubMed ID: 18451315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
    Lupica CR; Riegel AC
    Neuropharmacology; 2005 Jun; 48(8):1105-16. PubMed ID: 15878779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
    Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B
    Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.
    Cheer JF; Wassum KM; Sombers LA; Heien ML; Ariansen JL; Aragona BJ; Phillips PE; Wightman RM
    J Neurosci; 2007 Jan; 27(4):791-5. PubMed ID: 17251418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of CB1 receptors in psychostimulant addiction.
    Wiskerke J; Pattij T; Schoffelmeer AN; De Vries TJ
    Addict Biol; 2008 Jun; 13(2):225-38. PubMed ID: 18482432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
    Li F; Fang Q; Liu Y; Zhao M; Li D; Wang J; Lu L
    Eur J Pharmacol; 2008 Jul; 589(1-3):122-6. PubMed ID: 18534572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine.
    Filip M; Gołda A; Zaniewska M; McCreary AC; Nowak E; Kolasiewicz W; Przegaliński E
    Pharmacol Rep; 2006; 58(6):806-19. PubMed ID: 17220538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extinction learning of rewards in the rat: is there a role for CB1 receptors?
    Hernandez G; Cheer JF
    Psychopharmacology (Berl); 2011 Sep; 217(2):189-97. PubMed ID: 21519986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data.
    Maccioni P; Colombo G; Carai MA
    CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):55-9. PubMed ID: 20201816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats.
    Forget B; Barthélémy S; Saurini F; Hamon M; Thiébot MH
    Psychopharmacology (Berl); 2006 Nov; 189(1):59-69. PubMed ID: 16969683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo.
    Pillolla G; Melis M; Perra S; Muntoni AL; Gessa GL; Pistis M
    Psychopharmacology (Berl); 2007 Apr; 191(3):843-53. PubMed ID: 17334799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
    Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
    Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.
    Suplita RL; Eisenstein SA; Neely MH; Moise AM; Hohmann AG
    Neuropharmacology; 2008 Jan; 54(1):161-71. PubMed ID: 17714742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine.
    Vlachou S; Stamatopoulou F; Nomikos GG; Panagis G
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):905-23. PubMed ID: 18377702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
    Le Foll B; Forget B; Aubin HJ; Goldberg SR
    Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.
    Beardsley PM; Thomas BF; McMahon LR
    Int Rev Psychiatry; 2009 Apr; 21(2):134-42. PubMed ID: 19367507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.